Randomized controlled and double-blinded study of Caphosol versus saline oral rinses in pediatric patients with cancer.


Journal

Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624

Informations de publication

Date de publication:
10 2020
Historique:
received: 15 05 2020
accepted: 04 06 2020
pubmed: 30 7 2020
medline: 5 1 2021
entrez: 30 7 2020
Statut: ppublish

Résumé

Oral mucositis (OM) is a significant side effect of cancer treatment. The purpose of this study was to compare topically administered Caphosol to saline rinses in the prevention of mucositis in pediatric cancer patients. A controlled, double-blinded, and randomized clinical crossover study recruited patients between 2 to 17.99 years of age who were diagnosed with a malignancy and were receiving either high-dose methotrexate (≥1 g/m A total of 56 patients were recruited to the study, of whom 45 were randomized with a median age of 6.5 years (range 2.1-17.1 years). No cases of severe OM were observed. Grade ≥ 3 oral symptoms were present at least once in six (13%) patients during the Caphosol cycle and 13 (29%) patients during the saline cycle (P = .12). The peak of symptom scores was evident at around day 4-7 after administration of the chemotherapy with no marked differences between the rinse solutions. Multivariable regression analysis did not indicate a benefit of using Caphosol over the saline solution. No difference in prevention of oral mucositis was observed between the use of Caphosol or saline rinses.

Sections du résumé

BACKGROUND
Oral mucositis (OM) is a significant side effect of cancer treatment. The purpose of this study was to compare topically administered Caphosol to saline rinses in the prevention of mucositis in pediatric cancer patients.
PROCEDURE
A controlled, double-blinded, and randomized clinical crossover study recruited patients between 2 to 17.99 years of age who were diagnosed with a malignancy and were receiving either high-dose methotrexate (≥1 g/m
RESULTS
A total of 56 patients were recruited to the study, of whom 45 were randomized with a median age of 6.5 years (range 2.1-17.1 years). No cases of severe OM were observed. Grade ≥ 3 oral symptoms were present at least once in six (13%) patients during the Caphosol cycle and 13 (29%) patients during the saline cycle (P = .12). The peak of symptom scores was evident at around day 4-7 after administration of the chemotherapy with no marked differences between the rinse solutions. Multivariable regression analysis did not indicate a benefit of using Caphosol over the saline solution.
CONCLUSIONS
No difference in prevention of oral mucositis was observed between the use of Caphosol or saline rinses.

Identifiants

pubmed: 32725875
doi: 10.1002/pbc.28520
doi:

Substances chimiques

Mouthwashes 0
Saline Solution 0

Banques de données

ClinicalTrials.gov
['NCT02807337']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e28520

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Quinn B. Efficacy of supersaturated calcium phosphate oral rinse for the prevention and treatment of oral mucositis in patients receiving high dose cancer therapy: review of current data. Eur J Cancer Care. 2013;22(5):564-579.
Manji A, Tomlinson D, Ethier MC, Gassas A, Maloney AM, Sung L. Psychometric properties of the oral mucositis daily questionnaire for child self-report importance of mucositis in children treated with chemotherapy. Support Care Cancer. 2012;20(6):1251-1258.
Markiewicz M, Dzierzak M, Frankiewicz MA, et al. Treating oral mucositis with supersaturated calcium phosphate rinse: comparison with control in patients undergoing allogeneic hematopoietic stem cell transplantation. Support Care Cancer. 2012;20(9):2223-2229.
Svanberg A, Öhrn K, Birgegård G. Caphosol mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation. A pilot study. Eur J Oncol. 2015;19:50-53.
Pels E. Oral mucositis in children suffering from acute lymphoblastic leukaemia. Contemp Oncol (Pozn). 2012;16(1):12-15.
Ribeiro ILA, de Melo ACR, Limão NP, et al. Oral mucositis in pediatric oncology patients: a nested case-control to a prospective cohort. Braz Dent J. 2020;31(1):78-88.
Damascena LCL, de Lucena NNN, Ribeiro ILA, Pereira TL, Lima-Filho LMA, Valença AMG. Severe oral mucositis in pediatric cancer patients: survival analysis and predictive factors. Int J Environ Res Public Health. 2020;14(4):17.
Cheng KKF, Lee V, Li CH, et al. Impact of oral mucositis on short-term clinical outcomes in pediatric and adolescent patients undergoing chemotherapy. Support Care Cancer. 2013;21(8):2145-2152.
Al-Dasooqi N, Sonis ST, Bowen JM, et al. Emerging evidence on the pathobiology of mucositis. Support Care Cancer. 2013;21(11):3233-3241.
Miller MM, Donald DV, Hagemann TM. Prevention and treatment of oral mucositis in children with cancer. J Pediatr Pharmacol Ther. 2012;17(4):340-350.
Cheng KK. Oral mucositis: a phenomenological study of pediatric patients´ and their parents´ perspectives and experiences. Support Care Cancer. 2009;17(7):829-837.
Treister N, Nieder M, Baggott C, et al. Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation. Br J Cancer. 2017;116(1):21-27.
Murdock JL, Reeves DJ. Chemotherapy-induced oral mucositis management: a retrospective analysis of MuGard, Caphosol, and standard supportive care measures. J Oncol Pharm Pract. 2020;26:521-528.
Qutob AF, Allen G, Gue S, Revesz T, Logan RM, Keefe D. Implementation of a hospital oral care protocol and recording of oral mucositis in children receiving cancer treatment. Support Care Cancer. 2013;21(4):1113-1120.
Tomlinson D, Gibson F, Treister N, et al. Designing an oral mucositis assessment instrument for use in children: generating items using a nominal group technique. Support Care Cancer. 2009;17(5):555-562.
Cleveland WS, Grosse E, Shyu WM. Local regression models. In: Chambers JM, Hastie TJ, eds. Statistical Models. Wadsworth & Brooks/Cole; 1992.
Papas AS, Clark RE, Martuscelli G, O'Loughlin KT, Johansen E, Miller KB. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;31(8):705-712.
Rzepecki P, Wasko-Grabowska A, Oborska S. Use of a calcium phosphate mouth rinse for prevention of oral mucositis after haematopoietic stem cell transplantation - single center experience. Blood. 2009;114(22):4311.
Miyamoto CT, Wobb J, et al , A retrospective match controlled study of supersaturated calcium phosphate oral rinse vs. supportive care for radiation induced oral mucositis. Journal of Cancer Therapy. 2012;3(5):630-636.
Kiprian D, Jarzabski A, Kawecki A. Evaluation of efficacy of Caphosol in prevention and alleviation of acute side effects in patients treated with radiotherapy for head and neck cancers. Contemp Oncol (Pozn). 2016;20(5):389-393.
Wong KH, Kuciejewska A, Sharabiani MTA, et al. A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer. Radiother Oncol. 2017;122(2):207-211.
Lambrecht M, Mercier C, Geussen Y, Nuyts S. The effect of supersaturated calcium phosphate mouth rinse on the development of oral mucositis in head and neck cancer treated with (chemo)radiation. Support Care Cancer. 2013;21(10):2663-2670.
Raphael MF, Den Boer AM, Kollen WJ, et al. Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children. Results from a prospective multicenter double blind randomized controlled trial. Support Care Cancer. 2014;22(1):3-6.
Jacobs S, Baggott C, Agarwal R, et al. Validation of the Children's International Mucositis Evaluation Scale (ChIMES) in pediatric cancer and SCT. Br J Cancer. 2013;109(10):2515-2522.
Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients with cancer. Dent Clin North Am. 2008;52(1):61.

Auteurs

Egle Immonen (E)

Tampere Center for Child Health Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Department of Ear and Oral Diseases, Tampere University Hospital, Tampere, Finland.

Liisa Aine (L)

Department of Ear and Oral Diseases, Tampere University Hospital, Tampere, Finland.
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

Atte Nikkilä (A)

Tampere Center for Child Health Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

Mataleena Parikka (M)

Department of Ear and Oral Diseases, Tampere University Hospital, Tampere, Finland.
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

Marika Grönroos (M)

Department of Pediatrics, Turku University Hospital, Turku, Finland.

Kaisa Vepsäläinen (K)

Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland.

Sauli Palmu (S)

Tampere Center for Child Health Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

Mika Helminen (M)

Research, Development and Innovation Centre, Tampere University Hospital, Tampere, Finland.
Faculty of Social Sciences, Health Sciences, Tampere University, Tampere, Finland.

Timo Peltomäki (T)

Department of Ear and Oral Diseases, Tampere University Hospital, Tampere, Finland.
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Institute of Dentistry, University of Eastern Finland, Kuopio, Finland.

Olli Lohi (O)

Tampere Center for Child Health Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Tays Cancer Centre, Tampere University Hospital, Tampere, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH